Calidi Biotherapeutics, Inc. (CLDI) company profile
Close on Nov 17, 2026Market cap $1.45MP/E –Yield –
About Calidi Biotherapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. The company explores proprietary delivery and expression platforms designed to utilize oncolytic viruses and cell therapies to treat various solid tumors and oncological conditions. Its operations concentrate entirely on research and development activities in the biopharmaceutical space.
The company operates in the United States, maintaining its principal executive offices in San Diego, California. It conducts administrative, research, and managerial functions from this leased commercial facility. Calidi Biotherapeutics does not operate multiple commercial branches, retail locations, or distinct regional reporting segments, concentrating its primary organizational infrastructure and executive oversight at its headquarters location in California.
Summary of the business section of Calidi Biotherapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Calidi Biotherapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 4475 Executive Drive, Suite 200 92121
- Phone
- (858) 794-9600
- Website
- calidibio.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, Costa Mesa, California
Stock & identifiers
- Ticker
- CLDI
- Other tickers
- CLDWW
- Former tickers
- FLAG until Sep 19, 2023
- Exchange
- NYSE
- IPO date
- Sep 13, 2021
- Shares outstanding
- 3M, Aug 10, 2026
- Public float
- $8.00M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-16 reverse, Jul 31, 2026; 1-for-12 reverse, Aug 5, 2025; 1-for-10 reverse, Jul 15, 2024
- SEC CIK
- 1855485
- FIGI
- BBG012QFCL84
- Share class FIGI
- BBG012QFCL93
- EIN
- 86-2967193
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Santidrian Antonio Fernandez | Chief Scientific Officer | 327,788 |
| Eric E. Poma | Chief Executive Officer | 25,000 |
| Andrew C. Jackson | Chief Financial Officer | 2,500 |
| James A. Schoeneck | Director | 84,514 |
| Alan R. Stewart | Director | 28,976 |
| Corazon (Corsee) D. Sanders | Director | – |
| Scott Leftwich | Director | 146,631 |
| George Peoples | Director | – |
| Allan Camaisa | Director | 143,664 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Eric Poma Chief Executive Officer (3) | $358.04K | – | $267.97K | $47.89K | $673.90K | – |
| Allan J. Camaisa Director, Former Chief Executive Officer and Chairman of the Board | $148.85K | $80.00K | – | $753.82K | $982.66K | +93% |
| Andrew Jackson Chief Financial Officer | $430.00K | $75.25K | $36.33K | $52.38K | $593.97K | +15% |
| Antonio F. Santidrian Chief Scientific Officer and Head of Technical Operations | $399.00K | $70.00K | $42.38K | $65.61K | $576.99K | +31% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Sep 13, 2021
- Offer price
- $10.00
- Securities offered
- 20,000,000
- Gross proceeds
- $200.00M
- First trading day
- Nov 1, 2021
- First-day close
- $9.78-2.2%
- Lock-up ends (est.)
- Apr 30, 2022
“Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one-half of one redeemable warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
See a number that looks wrong?